Brian J Lannutti

Summary

Publications

  1. ncbi CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
    Brian J Lannutti
    Calistoga Pharmaceuticals Inc, Seattle, WA, USA
    Blood 117:591-4. 2011
  2. ncbi PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
    Sarah A Meadows
    Gilead Sciences Inc, Seattle, WA 98102, USA
    Blood 119:1897-900. 2012

Collaborators

Detail Information

Publications2

  1. ncbi CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
    Brian J Lannutti
    Calistoga Pharmaceuticals Inc, Seattle, WA, USA
    Blood 117:591-4. 2011
    ..These effects have been observed across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clinical evaluation of CAL-101...
  2. ncbi PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
    Sarah A Meadows
    Gilead Sciences Inc, Seattle, WA 98102, USA
    Blood 119:1897-900. 2012
    ..Our findings suggest that excessive PI3Kδ activity is characteristic in HL and support clinical evaluation of GS-1101, alone and in combination, as targeted therapy for HL...